Latest evidence for management of gout
Despite numerous national and international guidelines for gout (EULAR, ACR, BSR), there is poor uptake of urate-lowering therapies and there is a need to move towards a treat-to-target principle.
In a new Talking Rheumatology podcast episode from the British Society for Rheumatology, Dr Marwan Bukhari, editor in chief for Rheumatology, interviews consultant rheumatologists Edward Roddy and Kelsey Jordan to explore gout guidelines, what’s new and what changes are needed.
The new NICE guideline provides evidence-based recommendations for diagnosis and management of gout. They are freely available for health professionals, patients and commissioning bodies and are easy to read for lay people and non-medical professionals.
So, what are the take-home messages from the guidance?
- Febuxostat or allopurinol can be offered in equal weighting as first-line treatment.
- The recommended target serum urate level is below 360 micromol/litre, in line with both EULAR and ACR guidelines.
- The treat-to-target approach has been more strongly advocated.
- There is more emphasis on patient empowerment and discussion about use of urate lowering treatments at diagnosis.
- Follow-up with patients longer term with annual assessment of urate.
In the podcast, Edward Roddy explains, “We need a paradigm shift away from viewing gout as a self-inflicted condition because of lifestyle habits, and a shift away from management of inflammatory manifestations of gout and focus instead on urate lowering therapy.”
Find all the latest clinical guidelines from the British Society for Rheumatology.